{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000083","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.647098+00:00","generated_at":"2026-06-25T20:21:30.397506+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeoGenomics names Vishal Sikri President of Inivata; Dr. Clive Morris retiring in June","bullets":["Vishal Sikri appointed President and CCO of Inivata, effective May 23, 2022.","Dr. Clive Morris to retire as President of Inivata effective June 30, 2022; settlement terms not yet determined.","Dr. Gina Wallar, President of Pharma Services Division, resigning effective May 27, 2022; Jennifer Rose interim.","Sikri receives base salary $510K, annual bonus target 50% of salary, sign-on bonus $500K, and equity grant $1.055M."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000083","json":"https://secwatch.observer/filing/0001077183-22-000083.json","markdown":"https://secwatch.observer/filing/0001077183-22-000083.md","text":"https://secwatch.observer/filing/0001077183-22-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/0001077183-22-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/neo-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:21:30.397506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"976bd51b80","claim":"Clive D. Morris departed as President of Inivata at NEOGENOMICS INC.","evidence_excerpt":"On May 5, 2022, Dr. Clive D. Morris, NeoGenomics, Inc.’s (the “Company”) current President of Inivata, informed the Company of his intention to retire from his role effective June 30, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/0001077183-22-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"President of Inivata"}],"fact_type":"executive_change"},{"claim_id":"bdb3cd7af9","claim":"Vishal Sikri was appointed as President and Chief Commercial Officer, Inivata Division at NEOGENOMICS INC.","evidence_excerpt":"On May 9, 2022, the Company announced that Vishal Sikri, age 46, was appointed President and Chief Commercial Officer, Inivata Division, of the Company, effective May 23, 2022 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/0001077183-22-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Commercial Officer, Inivata Division"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}